Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren + valsartan + hydrochlorothiazide versus dual combinations in essential hypertension
2005-002635-27Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in essential hypertension comparing Aliskiren + valsartan + hydrochlorothiazide, Aliskiren + hydrochlorothiazide and Valsartan + hydrochlorothiazide (3 arms). Started Oct 2005; status: completed.
02
Drugs
aliskirenvalsartanhydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2005-002635-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002635-27.